Breaking News

Nestle Expands Skin Health Platform

May 28, 2014

To purchase key assets of Valeant Pharmaceutical for $1.4 billion.

Looks like Nestlé is serious about skin health. Today, the company said it will reinforce its newly-created Nestlé Skin Health unit with the the full rights to commercialize several key aesthetic dermatology products from Valeant Pharmaceuticals International. The $1.4 billion cash deal is for the US and Canada. The two markets together represent more than half of the fast-growing medical aesthetics market around the world. Galderma already commercialises the products included in this transaction outside those markets, according to Nestlé.

Under terms of the agreement, Nestlé is acquiring the full rights to commercialise in the US and Canada Restylane, Perlane and Emervel, products used for corrective facial aesthetic treatments, and Dysport, an aesthetic dermatology treatment. It will also acquire the full rights to Sculptra, a unique treatment for aesthetic and medical uses in the US, Canada and many markets around the world.

“With this deal we have acquired key strategic assets to extend Nestlé’s activities in the field of specialised, medical skin treatments, providing consumers with life-enhancing scientific products,” said Nestlé Chairman Peter Brabeck-Letmathe.

“This move will reinforce Galderma’s leading position in the industry when it becomes Nestlé Skin Health by allowing it to complete its geographic footprint for its strong portfolio of brands and leading medical solutions globally,” said Nestlé Chief Executive Paul Bulcke.

The transaction is subject to regulatory approval and customary closing conditions.

Back in February,  Nestlé announced it would extend its activities to include the field of specialized medical skin treatments through the creation of Nestlé Skin Health S.A., a global leader focused on meeting the world’s increasing skin health needs with a broad range of innovative and scientifically-proven products. The foundation for the company would be Galderma, the 50/50 joint venture with L’Oréal, which would become fully-owned by Nestlé. Bübchen, Nestlé's existing infant skin care business, would be merged into the new entity.

The acquisition of Galderma is awaiting final regulatory clearance.

 

Related End-User Markets:

Related Raw Materials:

blog comments powered by Disqus
  • Long Term Sustainability In the Nonwovens Market

    Long Term Sustainability In the Nonwovens Market

    August 23, 2016
    Learn more at Cleaning Products USA, Nov. 9-11, 2016

  • Fro Yo!

    Fro Yo!

    Tom Branna, Editorial Director||August 22, 2016
    Project Beauty dishes out Hairgurt, a line of vitamin-rich hair shampoos and conditioning masques.

  • TLC for Those Who Need It Most

    TLC for Those Who Need It Most

    Christine Esposito, Associate Editor||August 22, 2016
    New curriculum debuting at Bellus Academy helps estheticians treat a population that needs TLC.

  • Special Effects

    Special Effects

    Melissa Meisel, Associate Editor||August 1, 2016
    Fall 2016 color cosmetics reflect light and offer a focus on elements like pigment, slip and wear.

  • Silent Partners

    Silent Partners

    Christine Esposito, Associate Editor||August 1, 2016
    From research & development to logistics to confidentiality, savvy distributors help finished formulators achieve their goals

  • Sustainability is Omnipresent

    Sustainability is Omnipresent

    Christine Esposito , Associate Editor||July 1, 2016
    Industry stakeholders convene in New York City for Organic Monitor’s annual event